These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7852321)

  • 1. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization.
    Eldering E; Verpy E; Roem D; Meo T; Tosi M
    J Biol Chem; 1995 Feb; 270(6):2579-87. PubMed ID: 7852321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.
    Verpy E; Couture-Tosi E; Eldering E; Lopez-Trascasa M; Späth P; Meo T; Tosi M
    J Clin Invest; 1995 Jan; 95(1):350-9. PubMed ID: 7814636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
    Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
    J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
    Bos IG; Lubbers YT; Roem D; Abrahams JP; Hack CE; Eldering E
    J Biol Chem; 2003 Aug; 278(32):29463-70. PubMed ID: 12773530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule.
    Aulak KS; Eldering E; Hack CE; Lubbers YP; Harrison RA; Mast A; Cicardi M; Davis AE
    J Biol Chem; 1993 Aug; 268(24):18088-94. PubMed ID: 8349686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of serpin-protease complexes: antithrombin-thrombin, alpha 1-antitrypsin (358Met-->Arg)-thrombin, alpha 1-antitrypsin (358Met-->Arg)-trypsin, and antitrypsin-elastase.
    Whisstock J; Lesk AM; Carrell R
    Proteins; 1996 Nov; 26(3):288-303. PubMed ID: 8953650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
    Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
    Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of a noncovalent serpin-proteinase complex involves no conformational change in the serpin. Use of 1H-15N HSQC NMR as a sensitive nonperturbing monitor of conformation.
    Peterson FC; Gordon NC; Gettins PG
    Biochemistry; 2000 Oct; 39(39):11884-92. PubMed ID: 11009600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the specificity of serpin-protease complexes through interface analysis.
    Rashid Q; Kapil C; Singh P; Kumari V; Jairajpuri MA
    J Biomol Struct Dyn; 2015; 33(6):1352-62. PubMed ID: 25052369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251.
    Zahedi R; Aulak KS; Eldering E; Davis AE
    J Biol Chem; 1996 Sep; 271(39):24307-12. PubMed ID: 8798678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.
    Perlmutter DH; Glover GI; Rivetna M; Schasteen CS; Fallon RJ
    Proc Natl Acad Sci U S A; 1990 May; 87(10):3753-7. PubMed ID: 2160076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary structure changes stabilize the reactive-centre cleaved form of SERPINs. A study by 1H nuclear magnetic resonance and Fourier transform infrared spectroscopy.
    Perkins SJ; Smith KF; Nealis AS; Haris PI; Chapman D; Bauer CJ; Harrison RA
    J Mol Biol; 1992 Dec; 228(4):1235-54. PubMed ID: 1335516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing serpin reactive-loop conformations by proteolytic cleavage.
    Chang WS; Wardell MR; Lomas DA; Carrell RW
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):647-53. PubMed ID: 8670081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of mutant serpin/furin complexes: dependence on pH and regulation at the deacylation step.
    Dufour EK; Désilets A; Longpré JM; Leduc R
    Protein Sci; 2005 Feb; 14(2):303-15. PubMed ID: 15659365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into the mechanism of serpin-proteinase inhibition from 2D [1H-15N] NMR studies of the 69 kDa alpha 1-proteinase inhibitor Pittsburgh-trypsin covalent complex.
    Peterson FC; Gettins PG
    Biochemistry; 2001 May; 40(21):6284-92. PubMed ID: 11371190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1.
    Wardell MR; Chang WS; Bruce D; Skinner R; Lesk AM; Carrell RW
    Biochemistry; 1997 Oct; 36(42):13133-42. PubMed ID: 9335576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity and reactive loop length requirements for crmA inhibition of serine proteases.
    Tesch LD; Raghavendra MP; Bedsted-Faarvang T; Gettins PG; Olson ST
    Protein Sci; 2005 Feb; 14(2):533-42. PubMed ID: 15632287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium dodecyl sulfate-stable complexes between serpins and active or inactive proteinases contain the region COOH-terminal to the reactive site loop.
    Christensen S; Valnickova Z; Thøgersen IB; Pizzo SV; Nielsen HR; Roepstorff P; Enghild JJ
    J Biol Chem; 1995 Jun; 270(25):14859-62. PubMed ID: 7797463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin.
    Mast AE; Enghild JJ; Pizzo SV; Salvesen G
    Biochemistry; 1991 Feb; 30(6):1723-30. PubMed ID: 1704258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis.
    Mahadeva R; Dafforn TR; Carrell RW; Lomas DA
    J Biol Chem; 2002 Mar; 277(9):6771-4. PubMed ID: 11773044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.